Mandibular Bone Formation Rates in Aged Ovariectomized Rats Treated with Anti-resorptive Agents Alone and in Combination with Intermittent Parathyroid Hormone
Restricted accessOtherFirst published online June, 2000
Mandibular Bone Formation Rates in Aged Ovariectomized Rats Treated with Anti-resorptive Agents Alone and in Combination with Intermittent Parathyroid Hormone
Anti-resorptive agents-including estrogen (E), calcitonin (CT), and bisphosphonates-are established in the treatment of osteoporosis. Intermittent administration of parathyroid hormone (PTH) stimulates bone formation and is a possible therapeutic agent for the restoration of bone mass. The purpose was to determine the effects of the anti-resorptive agents alone and in combination with intermittent PTH on bone formation in the mandible and a long bone in the aged ovariectomized (Ovx) rat. Female rats were ovariectomized or sham-operated. One year later, groups of Ovx rats were treated with E, CT, or the bisphosphonate, Risedronate (NE). Additional groups of Ovx rats were treated with each of these agents in combination with human PTH for 10 weeks. Estrogen treatment suppressed most indices of bone formation in the humerus and mandible, while NE decreased some indices of formation at the endocortical and endosteal surfaces of the mandible and humerus. Increased double-labeled surface and mineral apposition rates were observed only on the mandibular endosteal surfaces following CT treatment. When the anti-resorptive agents were combined with intermittent PTH, most indices of bone formation at all skeletal sites were substantially greater than those of the untreated Ovx controls as well as the E-, CT-, and NE-treated groups, respectively. These results provide additional evidence that established and emerging therapies for osteoporosis affect osseous tissues in the oral cavity, and this may influence the progression of diseases and/or aging changes at this site.
Bagi CM, Miller SC, Bowman BM, Blomstrom GL, France EP (1992). Differences in cortical bone in overloaded and underloaded femurs from ovariectomized rats: comparison of bone morphometry with torsional testing. Bone13:35-40.
2.
Baumann BD, Wronski TJ (1995). Response of cortical bone to anti-resorptive agents and parathyroid hormone in aged ovariectomized rats. Bone16:247-253.
3.
Bell NH, Johnson RH (1997). Bisphosphonates in the treatment of osteoporosis . Endocrine6:203-206.
4.
Birkenfeld L., Yemini M., Kase NG, Birkenfeld A. (1999). Menopause-related oral alveolar bone resorption: a review of relatively unexplored consequences of estrogen deficiency. Menopause6:129-133.
5.
Brunsvold MA, Chaves ES, Komman KS, Aufdemorte TB, Wood R. ( 1992). Effects of a bisphosphonate on experimental periodontitis in monkeys. J Periodontol63:825-830.
6.
Dempster DW, Cosman F., Parisien M., Shen V., Lindsay R. (1993). Anabolic actions of parathyroid hormone on bone . Endocr Rev14:690-709.
7.
Ejersted C., Andreassen TT, Hauge E.-M, Melsen F., Oxlund H. (1995). Parathyroid hormone (1-34) increases vertebral bone mass, compressive strength, and quality in old rats. Bone17:507-511.
8.
Elovic RP, Hipp JA, Hayes WC (1995). Ovariectomy decreases the bone area fraction of the rat mandible. Calcif Tissue Int56:305-310.
9.
Fleisch H. (1998). Bisphosphonates: mechanisms of action. Endocr Rev19:80-100.
10.
Fox J., Miller MA, Stroup GB, Nemeth EF, Miller SC (1997). Plasma levels of parathyroid hormone that induce anabolic effects in bone of ovariectomized rats can be achieved by stimulation of endogenous hormone secretion. Bone21:163-169.
11.
Gasser JA, Jerome CP (1992). Parathyroid hormone: a cure for osteoporosis? Triangle31:111-121.
12.
Gotcher JE, Jee WS (1981). The progress of the periodontal syndrome in the rice rat. II. The effects of a diphosphonate on the periodontium. J Periodont Res16:441-455.
13.
Gunness-Hey M., Hock JM ( 1984). Increased trabecular bone mass in rats treated with human synthetic parathyroid hormone. Metab Bone Dis Relat Res5:177-181.
14.
Hildebolt CF (1997). Osteoporosis and oral bone loss. Dentomaxillofac Radiol26:3-15.
15.
Homer K., Devlin H., Alsop CW, Hodgkinson IM, Adams JE (1996). Mandibular bone mineral density as a predictor of skeletal osteoporosis. Br J Radiol69:1019-1025.
16.
Hsieh YD, Devlin H., McCord F. (1995). The effect of ovariectomy on the healing tooth socket of the rat. Arch Oral Biol40:529-531.
17.
Jacobs R., Ghyselen J., Koninckx P., van Steenberghe D. (1996). Long-term bone mass evaluation of mandible and lumbar spine in a group of women receiving hormone replacement therapy. Eur J Oral Sci104:10-16.
18.
Jahangiri L., Kim A., Nishimura I. (1997). Effect of ovariectomy on the local residual ridge remodeling. J Prosthet Dent77:435-443.
19.
Jeffcoat MK, Chesnut CH 3d (1993). Systemic osteoporosis and oral bone loss: evidence shows increased risk factors. J Am Dent Assoc124:49-56.
20.
Jerome CP, Johnson CS, Lees CJ ( 1995). Effect of treatment for 3 months with human parathyroid hormone 1-34 peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis) . Bone17(Suppl):415S-420S.
21.
Johnson RB, Gilbert JA, Cooper RC, Dai X., Newton BI, Tracy RR, et al. (1997). Alveolar bone loss one year following ovariectomy in sheep. JPeriodontol68:864-871.
22.
Kalu DN ( 1991). The ovariectomized rat model of postmenopausal bone loss . Bone Miner15:175-191.
23.
Kapetanos G., Symeonides PP, Dimitriou C., Karakatsanis K., Potoupnis M. (1997). A double blind study of intranasal calcitonin for established postmenopausal osteoporosis. Acta Orthop Scand275(Suppl): 108-111.
24.
Kowolik MJ, Hyvonen PM (1990). The effect of dichloromethylene bisphosphonate on human gingival crevicular neutrophil myeloperoxidase activity. Arch Oral Biol35(Suppl):201S-203S.
25.
Lindsay R. (1996). The menopause and osteoporosis. Obstet Gynecol87:16S-19S.
26.
Lucht U. (1973). Effects of calcitonin on osteoclasts in vivo: an ultrastructural and histochemical study. Z Zellforsch Mikrosk Anat145:75-87.
27.
Miller SC, Hunziker J., Mecham M., Wronski TJ (1997). Intermittent parathyroid hormone administration stimulates bone formation in the mandibles of aged ovariectomized rats. J Dent Res76 :1471-1476.
28.
Mohammad AR, Alder M., McNally MA (1996). A pilot study of panoramic film density at selected sites in the mandible to predict osteoporosis. Int J Prosthodont9:290-294.
29.
Mosekilde L., Søgaard CH, Danielsen CC, Torring 0 (1991). The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH-(1-34) and hPTH-(1-84). Endocrinology129:421-428.
30.
Paganini-Hill A. (1995). The benefits of estrogen replacement therapy on oral health. The Leisure World cohort. Arch Intern Med27:2325-2329.
31.
Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H., Meunier PJ, et al. (1987). Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res2:595-610.
32.
Qi H., Li M., Wronski TJ (1995). A comparison of the anabolic effects of parathyroid hormone at skeletal sites with moderate and severe osteopenia in aged ovariectomized rats. J Bone Miner Res10:948-955.
33.
Reddy MS, Weatherford TW 3rd, Smith CA, West BD, Jeffcoat MK, Jacks TM (1995). Alendronate treatment of naturally-occurring periodontitis in beagle dogs. J Periodontol66:211-217.
34.
Seeman E. (1997). Osteoporosis: trials and tribulations. Am J Med18:74S-87S.
35.
Shen V., Dempster DW, Mellish RW, Birchman R., Horbert W., Lindsay R. (1992). Effects of combined and separate intermittent administration of low-dose human parathyroid hormone fragment (1-34) and 17β-estradiol on bone histomorphometry in ovariectomized rats with established osteopenia . Calcif Tissue Int50:214-220.
36.
Shoji K., Horiuchi H., Shinoda H. (1995). Inhibitory effects of a bisphosphonate (risedronate) on experimental periodontitis in rats. J Periodont Res30:277-284.
37.
Taguchi A., Tanimoto K., Suei Y., Ohama K., Wada T. ( 1996a). Relationship between the mandibular and lumbar vertebral bone mineral density at different postmenopausal stages. Dentomaxillofac Radiol25:130-135.
38.
Taguchi A., Suei Y., Ohtsuka M., Otani K., Tanimoto K., Ohtaki M. (1996b). Usefulness of panoramic radiography in the diagnosis of postmenopausal osteoporosis in women. Width and morphology of inferior cortex of the mandible. Dentomaxillofac Radiol25:263-267.
39.
Taylor LM, Tertinegg I., Okuda A., Heersche JN (1989). Expression of calcitonin receptors during osteoclast differentiation in mouse metatarsals. J Bone Miner Res4:751-758.
40.
Teronen 0, Konttinen YT, Lindqvist C., Salo T., Ingman T., Lauhio A., et al. (1997). Human neutrophil collagenase MMP-8 in peri-implant sulcus fluid and its inhibition by clodronate. J Dent Res76:1529-1537.
von Wowem N., Klausen B., Kollerup G. (1994). Osteoporosis: a risk factor in periodontal disease . J Periodontol65:1134-1138.
43.
Wactawski-Wende J., Grossi SG, Trevisan M., Genco RJ, Tezal M., Dunford RG, et al. (1996). The role of osteopenia in oral bone loss and periodontal disease. J Periodontol67(Suppl): 1076-1084.
44.
Waynforth HB (1980). Experimental and surgical techniques in the rat . London: Academic Press.
45.
Weinreb M., Quartuccio H., Seedor JG, Aufdemorte TB, Brunsvold M., Chaves E., et al. (1994). Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys. J Periodont Res29:35-40.
46.
Wronski TJ, Yen C-F. (1991). The ovariectomized rat as an animal model for postmenopausal bone loss. Cells Mater1(Suppl):69-74.
47.
Wronski TJ, Yen CF, Qi H., Dann LM ( 1993). Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats. Endocrinology132:823-831.
